Neuropathic pain
Conditions
Interventions
Intervention group:Digital Cognitive Therapy combined with Conventional Treatment
Control group:Conventional Treatment
Sponsors
Beijing Jishuitan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with a confirmed diagnosis of neuropathic pain, according to the 2013 Expert Consensus on the Diagnosis and Treatment of Neuropathic Pain:(1) Pain localized within a defined neuroanatomical distribution;(2) Medical history indicating a relevant lesion or disease affecting the peripheral or central somatosensory system;(3) ID-Pain score >= 2;(4) LANSS score = 12;(5) DN4 score > 4. 2.Duration of pain >= 6 months. 3.Completion of at least 6 years of formal education. 4.Ability to communicate fluently in Mandarin Chinese. 5.Provision of written informed consent, with acknowledgment of the risks and benefits described in the consent form.
Exclusion criteria
Exclusion criteria: 1. Age < 18 years. 2. Previously diagnosed with dementia, or Mini-Mental State Examination (MMSE) score < 24. 3. Inability to complete cognitive or emotional assessments due to vision, hearing, or aphasia problems. 4. History of alcohol abuse or current use of medications affecting cognitive function (e.g., antihistamines, antipsychotics, hypnotics, anxiolytics, antidepressants). 5. Hamilton Depression Rating Scale (HAMD) score = 24 or Hamilton Anxiety Rating Scale (HAMA) score = 30. 6. History of stroke or traumatic brain injury within the past 6 months; history of intracranial tumor; or history of neurosurgical craniotomy. 7. History of Parkinson’s disease, Alzheimer’s disease, schizophrenia, or epilepsy. 8. Currently participating in another clinical drug trial that may significantly interfere with this study. 9. Patients who refuse to undergo cognitive assessments. 10. Any condition deemed by the investigator to make the patient unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in overall cognitive function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in sleep disturbances from baseline;Improvement in pain intensity;Improvements in cognitive function in individual cognitive domains compared with baseline;Changes in health status from baseline;Changes in anxiety and depression scores from baseline;Improvement in overall cognitive function; | — |
Countries
China
Contacts
Public ContactYan Zhou
Beijing Jishuitan Hospital, Capital Medical University
Outcome results
None listed